跳至主要内容
临床试验/CTRI/2025/02/080382
CTRI/2025/02/080382尚未招募2 期

Effectiveness of Individualized Homoeopathic Medicines in management of Depression, Anxiety & Stress in patients with non- communicable diseases A Multicentric randomized placebo- controlled trial

Central Council for Research in Homoeopathy4 个研究点 分布在 1 个国家目标入组 786 人开始时间: 2025年7月1日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
786
试验地点
4
主要终点
To evaluate the effectiveness of individualized homoeopathic medicines in the management of Depression, Anxiety & Stress in patients with non-communicable diseases using DASS21 score post intervention

研究概览

简要总结

A multicentric randomized placebo- controlled trial will be conducted to evaluate the effectiveness of individualized homoeopathic medicines in the management of Depression, Anxiety & Stress in patients with Non-Communicable diseases(NCDs).

Diagnosed cases of NCDs on medication with Mild, Moderate & Severe score on DASS-21 Scale will be included. Change in the DASS-21 scale post intervention will be assessed. Secondary Objectives will be to assess Change in WHO QoL Bref  Scale and Change in Depression, Anxiety & Stress and respective NCDs post intervention using validated scales and measures for each NCD.

In this Single Blind Randomized Controlled Trial, it is expected that individualized Homoeopathic medicines shall be effective in managing Depression, Anxiety and Stress in patients with Non-Communicable Diseases as compared to placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Both genders and Age from 18 to 70 years.
  • Diagnosed cases of non-communicable diseases on medication.
  • Mild, Moderate & Severe cases on DASS-21 Scale.
  • Patients willing to participate in the study.

排除标准

  • Patients suffering from any other known psychiatric and neurocognitive disorders (except depression, anxiety and stress).
  • Patient under “extremely severe” category on DASS-21 score.
  • Patients with uncontrolled NCDs even after medication.
  • Patients suffering from communicable diseases like HIV,TB, Hepatitis, Leprosy etc.
  • Patients suffering from complications of NCDs like Diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, Heart attack, Stroke, Acute limb ischaemia, acute respiratory distress syndrome, rheumatic heart disease, deep vein thrombosis, cor pulmonale, status asthmaticus, spontaneous pneumothorax, severe anaemia/neutropenia/sepsis/metastasis in cancer or any other Systemic diseases.
  • Pregnant and Lactating women.

结局指标

主要结局

To evaluate the effectiveness of individualized homoeopathic medicines in the management of Depression, Anxiety & Stress in patients with non-communicable diseases using DASS21 score post intervention

时间窗: Primary Outcome will be assessed at Baseline, after 2 weeks of Baseline and then every month for 6 months.

次要结局

  • 1.To assess the changes in Quality of Life of patients using WHOQOL Bref Scale.(2.To assess the changes in Depression, Anxiety & Stress along with changes in respective NCDs using validated scales & measures.)

研究者

发起方
Central Council for Research in Homoeopathy
申办方类型
Research institution
责任方
Principal Investigator
主要研究者

Dr Bharti Wadhwa

Central Council for Research in Homoeopathy

研究点 (4)

Loading locations...

相似试验